Table 1

Data that are collected for each patient entered in the International Vitreoretinal B-Cell Lymphoma Registry

ItemOptions (if relevant)
Baseline form
Patient demographics: gender; age at diagnosis; country of treatment; HIV infection status
Basis for first diagnosisCytology; immunophenotyping (immunocytochemistry, flow cytometry); PCR (IGH rearrangement, MyD88 mutation); cytokine analysis (interleukin 10, interleukin 10:interleukin 6)
Initial disease siteEye; brain parenchyma; spinal cord parenchyma; leptomeninges (including cerebrospinal fluid)
Mode of presentationNew onset disease; recurrent disease
Tissue involvementVitreous; retina (including retinal pigment epithelium); optic nerve; anterior segment
Visual acuity at presentation in Snellen (metres, feet or decimal) or Logmar
Follow-up form
Tissue involvementVitreous; retina; optic nerve
Visual acuity at end of interval in Snellen (metres, feet or decimal) or Logmar
Focal ocular treatmentIntraocular methotrexate (number of injections and dose); intraocular rituximab (number of injections and dose)
Ocular irradiationNumber of treatments and dose
ComplicationsKeratopathy; cataract; raised intraocular pressure/glaucoma; uveitis; retinopathy; maculopathy
Ocular statusComplete response; partial response; stable disease; progressive disease
Extraocular involvementBrain parenchyma; spinal cord parenchyma; leptomeninges (including cerebrospinal fluid)
Extensive treatmentSystemic chemotherapy; intrathecal chemotherapy; whole brain radiotherapy; stem cell transplantation
Complications of extensive treatmentLeukoencephalopathy; myelosuppression; infection; hepatotoxicity; ileus
Status at end of intervalAlive; deceased; unknown; revised/non-lymphoma diagnosis
If deceased: age at death; cause of death
  • Options include ‘other’, with boxes provided for free text.